BridgeBio Pharma (NASDAQ:BBIO) Stock, Quote.Headers.trade-ideas

BridgeBio Pharma

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.

bbio

Biotech

Large Cap

News

Health Care

Movers

General

BBIO

BridgeBio Pharma released Phase 1/2 trial results for BBP-631, its gene therapy for congenital adrenal hyperplasia. The study demonstrated increased cortisol production and reductions in key biomarkers. BridgeBio plans to seek partners for further development.

BridgeBio Pharma Seeks Partner To Develop Gene Therapy For Inherited Condition

movers image

Intraday Update

Markets

Trading Ideas

AAOI

AIRJ

BILI

KROS

NVAX

PCVX

PSNY

SHLS

VERA

XPEV

Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday

BAYRY

BridgeBio Pharma presented additional data from its Phase 3 ATTRibute-CM study of acoramidis in ATTR-CM at the European Society of Cardiology 2024, showing increased serum TTR levels in participants who switched from placebo and tafamidis to acoramidis.

Why Is BridgeBio Pharma Stock Trading Higher On Friday?

BridgeBio Pharma Inc

<p>Investors might want to bet on <strong>Camden National</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cac#NASDAQ">CAC</a>), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.</p>
<p>A company&#39;s changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.</p>
<p>The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.</p>
<p>Therefore, the Zacks rating upgrade for Camden National basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.</p>
<h2>Most Powerful Force Impacting Stock Prices</h2>
<p>The change in a company&#39;s future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company&#39;s shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.</p>
<p>For Camden National, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company&#39;s underlying business. And investors&#39; appreciation of this improving business trend should push the stock higher.</p>
<h2>Harnessing the Power of Earnings Estimate Revisions</h2>
<p>Empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.</p>
<p>The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988.</p>
<h2>Earnings Estimate Revisions for Camden National</h2>
<p>This bank is expected to earn $3.33 per share for the fiscal year ending December 2024, which represents a year-over-year change of -8.3%.</p>
<p>Analysts have been steadily raising their estimates for Camden National. Over the past three months, the Zacks Consensus Estimate for the company has increased 6.4%.</p>
<h2>Bottom Line</h2>
<p>Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of &#39;buy&#39; and &#39;sell&#39; ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a &#39;Strong Buy&#39; rating and the next 15% get a &#39;Buy&#39; rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.</p>
<p>The upgrade of Camden National to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.</p>
<p><a href="https://www.zacks.com/stock/news/2340062/what-makes-camden-national-cac-a-new-strong-buy-stock?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2340062">To read this article on Zacks.com click here.</a></p>


Earnings

Small Cap

Analyst Ratings

What Makes Camden National a New Strong Buy Stock

<p>Momentum investing is all about the idea of following a stock&#39;s recent trend, which can be in either direction. In the &#39;long&#39; context, investors will essentially be &quot;buying high, but hoping to sell even higher.&quot; And for investors following this methodology, taking advantage of trends in a stock&#39;s price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.</p>
<p>Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.</p>
<p>Below, we take a look at <strong>Canadian Imperial Bank</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cm#NYSE">CM</a>), a company that currently holds a Momentum Style Score of B. We also talk about price change and earnings estimate revisions, two of the main aspects of the Momentum Style Score.</p>
<p>It&#39;s also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Canadian Imperial Bank currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period.</p>
<h2>Set to Beat the Market?</h2>
<p>Let&#39;s discuss some of the components of the Momentum Style Score for CM that show why this bank and financial services company shows promise as a solid momentum pick.</p>
<p>Looking at a stock&#39;s short-term price activity is a great way to gauge if it has momentum, since this can reflect both the current interest in a stock and if buyers or sellers have the upper hand at the moment. It&#39;s also helpful to compare a security to its industry; this can show investors the best companies in a particular area.</p>
<p>For CM, shares are up 0.37% over the past week while the Zacks Banks - Foreign industry is up 1.99% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 13.34% compares favorably with the industry&#39;s 1.97% performance as well.</p>
<p>While any stock can see a spike in price, it takes a real winner to consistently outperform the market. Over the past quarter, shares of Canadian Imperial Bank have risen 29.74%, and are up 53.89% in the last year. On the other hand, the S&amp;P 500 has only moved 4.57% and 31.09%, respectively.</p>
<p>Investors should also take note of CM&#39;s average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. Right now, CM is averaging 1,548,275 shares for the last 20 days.</p>
<h2>Earnings Outlook</h2>
<p>The Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have recently been seeing that with CM.</p>
<p>Over the past two months, 6 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost CM&#39;s consensus estimate, increasing from $5.05 to $5.36 in the past 60 days. Looking at the next fiscal year, 6 estimates have moved upwards while there have been no downward revisions in the same time period.</p>
<h2>Bottom Line</h2>
<p>Taking into account all of these elements, it should come as no surprise that CM is a #2 (Buy) stock with a Momentum Score of B. If you&#39;ve been searching for a fresh pick that&#39;s set to rise in the near-term, make sure to keep Canadian Imperial Bank on your short list.</p>
<p><a href="https://www.zacks.com/stock/news/2340059/are-you-looking-for-a-top-momentum-pick-why-canadian-imperial-bank-cm-is-a-great-choice?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_10-2340059">To read this article on Zacks.com click here.</a></p>


Short Ideas

Are You Looking for a Top Momentum Pick? Why Canadian Imperial Bank is a Great Choice

Rumors

NBBK

Watching NB Bancorp; Shares See Volume As Traders Circulate The Stock Was Picked By A Popular Newsletter Service

<p>Financial giants have made a conspicuous bearish move on Oracle. Our analysis of options history for Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) revealed 34 unusual trades.</p>
<p>Delving into the details, we found 32% of traders were bullish, while 52% showed bearish tendencies. Out of all the trades we spotted, 18 were puts, with a value of $1,086,034, and 16 were calls, valued at $1,249,671.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $100.0 to $190.0 for Oracle during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Oracle's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Oracle's whale activity within a strike price range from $100.0 to $190.0 in the last 30 days. </p>
<h3>Oracle 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727119880_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ORCL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$4.45</td>
<td>$4.3</td>
<td>$4.3</td>
<td>$155.00</td>
<td>$451.5K</td>
<td>1.4K</td>
<td>1.0K</td>
</tr>
<tr>
<td>ORCL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$7.1</td>
<td>$7.05</td>
<td>$7.05</td>
<td>$165.00</td>
<td>$369.4K</td>
<td>3.2K</td>
<td>561</td>
</tr>
<tr>
<td>ORCL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$2.76</td>
<td>$2.71</td>
<td>$2.71</td>
<td>$167.50</td>
<td>$144.1K</td>
<td>0</td>
<td>837</td>
</tr>
<tr>
<td>ORCL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$4.2</td>
<td>$4.15</td>
<td>$4.2</td>
<td>$170.00</td>
<td>$141.1K</td>
<td>4.7K</td>
<td>546</td>
</tr>
<tr>
<td>ORCL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/27/24</td>
<td>$14.05</td>
<td>$12.9</td>
<td>$14.04</td>
<td>$152.50</td>
<td>$87.0K</td>
<td>95</td>
<td>62</td>
</tr>
</tbody>
</table>
</p>
<h3>About Oracle</h3>
<p>Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.</p>
<p>In light of the recent options history for Oracle, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Where Is Oracle Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 4,549,439, the ORCL's price is down by -1.49%, now at $165.49. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 77 days.</li>
</ul>
<h3>What Analysts Are Saying About Oracle</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $165.6.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Morgan Stanley persists with their Equal-Weight rating on Oracle, maintaining a target price of $145.<br />
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Neutral rating for Oracle, targeting a price of $140.<br />
&#x2A; Maintaining their stance, an analyst from TD Cowen continues to hold a Buy rating for Oracle, targeting a price of $180.<br />
&#x2A; An analyst from BMO Capital persists with their Market Perform rating on Oracle, maintaining a target price of $173.<br />
&#x2A; Maintaining their stance, an analyst from Keybanc continues to hold a Overweight rating for Oracle, targeting a price of $190. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Oracle options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

ORCL

Oracle Unusual Options Activity

<p>Deep-pocketed investors have adopted a bullish approach towards Rocket Lab USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in RKLB usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Rocket Lab USA. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 55% leaning bullish and 22% bearish. Among these notable options, 2 are puts, totaling $204,250, and 7 are calls, amounting to $328,871.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $4.0 and $15.0 for Rocket Lab USA, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Rocket Lab USA's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Rocket Lab USA's significant trades, within a strike price range of $4.0 to $15.0, over the past month.</p>
<h3>Rocket Lab USA Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727119875_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>RKLB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$2.15</td>
<td>$2.05</td>
<td>$2.15</td>
<td>$7.00</td>
<td>$139.9K</td>
<td>1.5K</td>
<td>1.0K</td>
</tr>
<tr>
<td>RKLB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$5.1</td>
<td>$4.6</td>
<td>$5.0</td>
<td>$4.00</td>
<td>$100.0K</td>
<td>127</td>
<td>201</td>
</tr>
<tr>
<td>RKLB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$2.2</td>
<td>$2.15</td>
<td>$2.15</td>
<td>$7.00</td>
<td>$64.2K</td>
<td>1.5K</td>
<td>299</td>
</tr>
<tr>
<td>RKLB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$2.85</td>
<td>$2.65</td>
<td>$2.85</td>
<td>$12.00</td>
<td>$57.0K</td>
<td>637</td>
<td>0</td>
</tr>
<tr>
<td>RKLB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$1.8</td>
<td>$1.6</td>
<td>$1.72</td>
<td>$12.00</td>
<td>$51.6K</td>
<td>5.7K</td>
<td>629</td>
</tr>
</tbody>
</table>
</p>
<h3>About Rocket Lab USA</h3>
<p>Rocket Lab USA Inc is engaged in space, building rockets, and spacecraft. It provides end-to-end mission services that provide frequent and reliable access to space for civil, defense, and commercial markets. It designs and manufactures the Electron and Neutron launch vehicles and Photon satellite platform. Rocket Lab's Electron launch vehicle has delivered multiple satellites to orbit for private and public sector organizations, enabling operations in national security, scientific research, space debris mitigation, Earth observation, climate monitoring, and communications. The business operates in two segments being Launch Services and Space systems. Geographically it serves Japan, Germany, rest of the world and earns key revenue from the United States.</p>
<p>Following our analysis of the options activities associated with Rocket Lab USA, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of Rocket Lab USA</h3>
<ul>
<li>With a volume of 7,745,020, the price of RKLB is up 2.14% at $7.63. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 44 days.</li>
</ul>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Rocket Lab USA options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


RKLB

Rocket Lab USA Options Trading: A Deep Dive into Market Sentiment

<p>Financial giants have made a conspicuous bearish move on ConocoPhillips. Our analysis of options history for ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>) revealed 9 unusual trades.</p>
<p>Delving into the details, we found 22% of traders were bullish, while 44% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $185,205, and 6 were calls, valued at $315,113.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $105.0 to $125.0 for ConocoPhillips during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in ConocoPhillips's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to ConocoPhillips's substantial trades, within a strike price spectrum from $105.0 to $125.0 over the preceding 30 days.</p>
<h3>ConocoPhillips Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727119870_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>COP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$0.55</td>
<td>$0.48</td>
<td>$0.55</td>
<td>$125.00</td>
<td>$108.6K</td>
<td>3.6K</td>
<td>1.9K</td>
</tr>
<tr>
<td>COP</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.65</td>
<td>$4.5</td>
<td>$4.6</td>
<td>$105.00</td>
<td>$90.6K</td>
<td>2.5K</td>
<td>402</td>
</tr>
<tr>
<td>COP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.55</td>
<td>$4.45</td>
<td>$4.55</td>
<td>$105.00</td>
<td>$68.7K</td>
<td>2.5K</td>
<td>151</td>
</tr>
<tr>
<td>COP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>10/25/24</td>
<td>$1.34</td>
<td>$1.2</td>
<td>$1.3</td>
<td>$114.00</td>
<td>$66.9K</td>
<td>22</td>
<td>516</td>
</tr>
<tr>
<td>COP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$2.09</td>
<td>$2.05</td>
<td>$2.05</td>
<td>$110.00</td>
<td>$46.6K</td>
<td>4.3K</td>
<td>311</td>
</tr>
</tbody>
</table>
</p>
<h3>About ConocoPhillips</h3>
<p>ConocoPhillips is a US-based independent exploration and production firm. In 2023, it produced 1.2 million barrels per day of oil and natural gas liquids and 3.1 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2023 were 6.8 billion barrels of oil equivalent.</p>
<p>In light of the recent options history for ConocoPhillips, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of ConocoPhillips</h3>
<ul>
<li>Currently trading with a volume of 5,277,196, the COP's price is up by 0.14%, now at $110.02. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 38 days.</li>
</ul>
<h3>What The Experts Say On ConocoPhillips</h3>
<p>A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $139.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Buy rating on ConocoPhillips with a target price of $140.<br />
&#x2A; Maintaining their stance, an analyst from Mizuho continues to hold a Neutral rating for ConocoPhillips, targeting a price of $129.<br />
&#x2A; Consistent in their evaluation, an analyst from Susquehanna keeps a Positive rating on ConocoPhillips with a target price of $147.<br />
&#x2A; An analyst from RBC Capital downgraded its action to Outperform with a price target of $140. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for ConocoPhillips with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Check Out What Whales Are Doing With COP

<p><strong>V2X</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vvx#NYSE">VVX</a>) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.</p>
<p>The sole determinant of the Zacks rating is a company&#39;s changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.</p>
<p>The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.</p>
<p>Therefore, the Zacks rating upgrade for V2X basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.</p>
<h2>Most Powerful Force Impacting Stock Prices</h2>
<p>The change in a company&#39;s future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company&#39;s shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.</p>
<p>For V2X, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company&#39;s underlying business. And investors&#39; appreciation of this improving business trend should push the stock higher.</p>
<h2>Harnessing the Power of Earnings Estimate Revisions</h2>
<p>Empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.</p>
<p>The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988.</p>
<h2>Earnings Estimate Revisions for V2X</h2>
<p>For the fiscal year ending December 2024, this government services company is expected to earn $4.11 per share, which is a change of 9.9% from the year-ago reported number.</p>
<p>Analysts have been steadily raising their estimates for V2X. Over the past three months, the Zacks Consensus Estimate for the company has increased 0.6%.</p>
<h2>Bottom Line</h2>
<p>Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of &#39;buy&#39; and &#39;sell&#39; ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a &#39;Strong Buy&#39; rating and the next 15% get a &#39;Buy&#39; rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.</p>
<p>The upgrade of V2X to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.</p>
<p><a href="https://www.zacks.com/stock/news/2340061/v2x-vvx-upgraded-to-buy-here-s-what-you-should-know?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2340061">To read this article on Zacks.com click here.</a></p>


Upgrades

V2X Upgraded to Buy: Here's What You Should Know

<p>FTAI Aviation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>) has outperformed the market over the past 5 years by 44.29% on an annualized basis producing an average annual return of 58.3%. Currently, FTAI Aviation has a market capitalization of $13.43 billion. </p>
<p><strong>Buying $100 In FTAI:</strong> If an investor had bought $100 of FTAI stock 5 years ago, it would be worth <strong>$987.58</strong> today based on a price of $131.40 for FTAI at the time of writing.</p>
<h3>FTAI Aviation's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727119815_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


FTAI

$100 Invested In This Stock 5 Years Ago Would Be Worth $1,000 Today

<p>H&amp;R Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRB#NYSE">HRB</a>) has outperformed the market over the past 5 years by 8.51% on an annualized basis producing an average annual return of 22.52%. Currently, H&amp;R Block has a market capitalization of $9.00 billion. </p>
<p><strong>Buying $100 In HRB:</strong> If an investor had bought $100 of HRB stock 5 years ago, it would be worth <strong>$272.50</strong> today based on a price of $64.46 for HRB at the time of writing.</p>
<h3>H&amp;R Block's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727119810_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$100 Invested In H&R Block 5 Years Ago Would Be Worth This Much Today

<p><strong>Citigroup Inc</strong>.&#39;s (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/c#NYSE">C</a>) plan to expand in China has met a snag with the U.S. regulators after the Federal Reserve imposed a penalty on the bank related to its data management and risk controls, per a Bloomberg report.</p>
<p>The bank is currently awaiting a clearance letter from the U.S. Federal Reserve, which is required by Chinese authorities to verify Citigroup&#39;s regulatory standing. Without this letter, the bank cannot proceed with its plans to set up a standalone securities firm in China.</p>
<p>The difficulties arose when Citigroup was fined $136 million in July 2024 for failing to address its data management issues adequately. The regulators stated that Citigroup made &quot;insufficient progress&quot; in dealing with the issues identified in 2020, which required Citi to fix these issues in its enterprise-wide risk management, compliance risk management, data governance and internal controls.</p>
<p>These fines complicated C&#39;s ability to comply with China&#39;s licensing requirements, making its path to expansion more challenging.</p>
<p>However, according to a Bloomberg report, citing people familiar with the matter, the bank remains actively engaged in discussions with China&#39;s securities regulator regarding its application for the new business and has no intention to withdraw its application.</p>
<h2>Citigroup&#39;s Prior Regulatory Issues</h2>
<p>Apart from the fine levied on the bank in July, Citigroup has been facing some other regulatory scrutiny as well. In August, the bank made the headlines for repeatedly breaching the Federal Reserve&#39;s Regulation W, which limits intercompany transactions. Those breaches led to discrepancies in the company&#39;s internal liquidity reporting. This was reported by Reuters, citing an internal company document.</p>
<p>In May, Citigroup was fined $78.4 million by a pair of British regulators due to the bank&#39;s deficiencies in the systems and controls. These flaws led a trader to make an inputting error that caused a flash crash in May 2022. The penalty amount consisted of &pound;27.8 million from the Financial Conduct Authority and &pound;33.9 million from the Bank of England&#39;s Prudential Regulation Authority.</p>
<p>In June, the Federal Reserve and the Federal Deposit Insurance Corporation (FDIC) stated that they had observed shortcomings in the &lsquo;living wills&#39; of Citigroup, <strong>JPMorgan Chase</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jpm#NYSE">JPM</a>) and <strong>Goldman Sachs</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gs#NYSE">GS</a>). Per agencies, the shortcomings raise doubts about their plan&#39;s feasibility. JPM had minor problems that the Fed and the FDIC found, claiming that its systems for unwinding specific derivatives trades had not been thoroughly tested. GS was criticized for not providing &lsquo;trade-level&#39; details on its derivatives transactions.</p>
<p>The FDIC chastised Citigroup, stating that the bank&#39;s resolution plan was either not credible or would not enable a smooth bankruptcy process following U.S. laws. Apart from the problem with its derivatives portfolio, the regulators stated that the company had neglected to address concerns regarding its &quot;resolution data integrity and data management issues.&quot;</p>
<p>These ongoing regulatory litigations and penalties are significant obstacles for the bank, potentially increasing costs and impacting bottom-line growth.</p>
<p>Over the past six months, shares of C have gained 2% compared with the industry&#39;s growth of 8.8%.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/9b/78841.jpg?v=763969543" /></p>
<p>Image Source: Zacks Investment Research</p>
<p>Currently, C carries a Zacks Rank #3 (Hold).</p>
<p><a href="https://www.zacks.com/stock/news/2340076/citigroup-s-china-expansion-plans-stalled-amid-regulatory-probes?cid=CS-BENZ-FT-analyst_blog|company_news_finance_sector-2340076">To read this article on Zacks.com click here.</a></p>


Asia

Government

Regulations

Management

Events

Federal Reserve

Citigroup's China Expansion Plans Stalled Amid Regulatory Probes

<p><strong>Baidu Inc</strong> (NASDAQ BIDU) shares are trading higher by 2.56% to $88.45 going into the close of Monday&#8217;s session as investors reacted positively to the <strong>People's Bank of China's (PBoC)</strong> <a href="https://www.benzinga.com/markets/asia/24/09/40986319/chinese-stocks-defy-bidens-auto-import-ban-concerns-rally-to-4-month-highs-as-central-bank-unexpecte">surprise interest rate cut</a>.</p>
<p>The central bank's decision to lower the 14-day reverse repurchase rate by 10 basis points, alongside a liquidity injection of over $10 billion, has fueled optimism for economic recovery in <strong>China</strong>.</p>
<p><strong>What This Matters:</strong> The PBoC's move impacts technology companies like Baidu, which play a central role in China's growth strategy. Baidu, often dubbed the &#8220;Google of China,&#8221; has evolved beyond its core search engine business to become a leader in <a href="https://www.benzinga.com/topic/artificial-intelligence">artificial intelligence (AI)</a>, autonomous driving and cloud computing.</p>
<p>The rate cut, which reduces business borrowing costs, is expected to encourage increased spending in the technology sector. This could drive greater demand for Baidu's AI and cloud services, as enterprises look to enhance their digital infrastructure amid favorable financial conditions.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40987087/us-stocks-stall-gold-updates-record-highs-tesla-rallies-whats-driving-markets-monday">US Stocks Stall, Gold Updates Record Highs, Tesla Rallies: What&#8217;s Driving Markets Monday?</a></strong></p>
<p><strong>What Else:</strong> Baidu's autonomous driving platform, <strong>Apollo</strong>, also benefits from increased investment and consumption as liquidity flows through the economy. Baidu pioneered the development of robotaxis and smart city infrastructure in China; these sectors could receive further governmental support as part of Beijing's push to modernize the country's technological backbone.</p>
<p>With lower borrowing costs and potential government-backed stimulus for innovation, Baidu's efforts in autonomous mobility and AI-driven services are well-positioned for growth.</p>
<p>Additionally, as liquidity enters the market, Baidu's core digital advertising business is poised for an uplift. The company generates a significant portion of its revenue from online advertising, which tends to rise in tandem with broader economic activity. </p>
<p>With businesses likely to increase marketing budgets in response to anticipated consumer spending, Baidu could see a resurgence in advertising revenues.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40989179/meta-connect-2024-preview-cheaper-vr-expected-analysts-see-augmented-reality-and-ai">Meta Connect 2024 Preview: Cheaper VR Expected, Analysts See Augmented Reality And AI As Major Focus</a></strong></p>
<h2 class="wp-block-heading">How To Buy BIDU Stock</h2>
<p>By now you're likely curious about how to participate in the market for Baidu &#8211; be it to purchase shares, or even attempt to bet against the company.</p>
<p>Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so. </p>
<p>If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.</p>
<p>According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, BIDU has a 52-week high of $136.53 and a 52-week low of $79.68.</p>


BIDU

Why Baidu Stock Is Moving

<p>Less than two months before the Nov. 5 election, when <a href="https://www.benzinga.com/markets/cannabis/24/08/40327596/will-north-dakota-legalize-adult-use-marijuana-voters-to-decide-in-november">cannabis adult-use</a> will be voted in North Dakota, two Catholic bishops from the State are urging voters to reject Measure 5.</p>
<p>Bishops <strong>David Kagan</strong> of Bismarck and <strong>John Folda</strong> of Fargo issued a joint statement to parishioners on Sept. 10, warning that cannabis legalization will harm "individuals, families, and communities."</p>
<p>If passed, the measure would legalize recreational cannabis for adults 21 and over<strong>. </strong>Measure 5 would allow adults to grow, possess, and sell cannabis legally in <a href="https://www.benzinga.com/topic/north-dakota">North Dakota</a>.</p>
<p>This marks the third time voters will decide on the issue, following similar proposals that were rejected in 2018 and 2022.</p>
<h3 class="wp-block-heading">Bishops' Concerns Rooted In Doctrine</h3>
<p>The bishops grounded their opposition in the teachings of the Catholic Church, <a href="https://cruxnow.com/church-in-the-usa/2024/09/north-dakota-bishops-advocate-against-marijuana-legalization">reported</a> Catholic news site Crux.</p>
<p>Citing the Catechism, they reminded the faithful that "the use of drugs inflicts very grave damage on human health and life." </p>
<p>The bishops argue that regular cannabis use impairs brain function, harms lung health, and believe that cannabis can worsen mental health issues.</p>
<p>"Cannabis is not the harmless drug that some imagine it to be," Kagan and Folda said. They argue that cannabis often acts as a gateway to harder drugs, compounding their concerns. Studies <a href="https://www.benzinga.com/general/biotech/23/01/30631570/recreational-cannabis-legalization-correlated-with-decrease-in-alcohol-use-disorder-new-study-fin">dispute this claim</a>. </p>
<p><strong>Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40964435/was-cannabis-the-secret-to-jesus-healing-miracles-study-uncovers-ancient-remedies">Was Cannabis The Secret To Jesus&#8217; Healing Miracles? Study Uncovers Ancient Remedies</a></strong></p>
<h3 class="wp-block-heading">There&#8217;s Also Opposition From Medical Leaders</h3>
<p><strong>Stephanie Dahl</strong>, president of the North Dakota Medical Association, echoed the bishops' concerns, emphasizing that "cannabis use is not without risk." </p>
<p><strong>Tim Blasl</strong>, president of the North Dakota Hospital Association, added that the state should focus on substance abuse prevention and education instead of legalization. </p>
<p>"We continue to experience an epidemic of behavioral health issues in our communities," Blasl said, stressing the need to prioritize public health over recreational drug use.</p>
<p><strong><em>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</em></strong></p>
<h3 class="wp-block-heading">Advocates Push For Legalization</h3>
<p>Instead, Measure 5's supporters, led by <strong>New Economic Frontier</strong>, see cannabis legalization as an <a href="https://www.benzinga.com/markets/cannabis/24/05/38712820/legal-cannabis-states-raked-in-20b-since-2014-peaking-at-4b-in-2023-new-report-shows">economic opportunity </a>for the state. </p>
<p>They argue that legalization will boost <a href="https://www.benzinga.com/markets/cannabis/23/10/35244369/cannabis-tax-map-see-how-states-are-cashing-in">tax revenue</a>, <a href="https://www.benzinga.com/markets/cannabis/24/07/39892433/dea-rescheduling-of-cannabis-could-create-over-50-000-jobs-industry-group-notes-in-public-commen">create jobs</a>, and reduce strain on law enforcement. Proponents also believe it will bring clarity and safety to workplaces through proper regulation.</p>
<p>Advocates point to the 24 states and Washington, D.C., that have already l<a href="https://www.benzinga.com/topic/legal-cannabis">egalized recreational cannabis</a>. They highlight Colorado as an example of economic success, noting that the cannabis industry has grown into a billion-dollar market since legalization. </p>
<p>They also argue that in states with legal cannabis, <a href="https://www.benzinga.com/markets/cannabis/23/08/33606242/cannabis-can-help-reduce-unregulated-opioid-use-and-manage-cravings-study-finds">opioid use</a> has decreased, potentially saving lives.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/02/37166627/exclusive-undo-the-harms-of-the-war-on-drugs-says-glass-house-ceo">EXCLUSIVE: &#8216;Undo The Harms Of The War On Drugs,&#8217; Says Glass House CEO</a></strong></p>
<h3 class="wp-block-heading">The Broader Picture</h3>
<p>The debate around cannabis in North Dakota is not new, but the arguments remain contentious. </p>
<p>Supporters claim the economic benefits and social justice reforms outweigh potential risks. They argue that cannabis legalization could help with disproportionately impacted marginalized communities. This mirrors the position of cannabis advocates nationwide, who continue to push for policies that bring both economic growth and social equity.</p>
<p>Opponents remain concerned about public health and safety. </p>
<p>In this particular case, the bishops argue that cannabis use inflicts "grave damage on human health." But recent studies challenge this notion, comparing cannabis to substances like alcohol and opioids. Research suggests that regular cannabis use is less likely to harm others compared to alcohol or opioid use. In fact, secondhand harm from cannabis appears to be far lower than that caused by alcohol abuse. </p>
<p>These findings call into question the Church&#8217;s broader stance on drug use, especially as legal cannabis gains wider acceptance.</p>
<p>Moreover, cannabis advocates argue that the so called &#8216;War on Drugs&#8217; has caused far more harm than cannabis legalization ever could. Many people, especially from marginalized communities, continue to serve lengthy prison sentences for nonviolent cannabis offenses. At the same time, legal cannabis businesses thrive. </p>
<p>Advocates like <strong>Glass House</strong> CEO <strong>Steve Kazan</strong>, have called this contrast <a href="https://www.benzinga.com/markets/cannabis/24/02/37166627/exclusive-undo-the-harms-of-the-war-on-drugs-says-glass-house-ceo">"insane"</a> and push for legal reforms to rectify these social injustices.</p>
<p>If you are curious about the content of Measure 5, you will find the ballot text in <a href="https://www.sos.nd.gov/elections/voter/ballot-measures/measures-ballot">here</a>.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cannabis/24/02/37166627/exclusive-undo-the-harms-of-the-war-on-drugs-says-glass-house-ceo">EXCLUSIVE: &#8216;Undo The Harms Of The War On Drugs,&#8217; Says Glass House CEO</a></strong></li>
</ul>
<p><em>Cover: AI generated image</em></p>


Cannabis

Politics

Cassocks Vs. Cannabis: North Dakota Bishops Take Aim At November's Legalization Ballot

<p><a href="https://wccftech.com/nvidia-h20-ai-accelerators-next-us-ban-rumor-stops-taking-new-orders-china/">https://wccftech.com/nvidia-h20-ai-accelerators-next-us-ban-rumor-stops-taking-new-orders-china/</a></p>
<p>NVIDIA's "China-compliant" H20 AI accelerators might face the next US ban "hammer" as Team Green stops taking additional orders from Chinese clients.</p>
<h2><strong>The US Is Looking To Expand Its Export Restrictions By Banning NVIDIA's "China-Compliant" H20 AI Accelerator</strong></h2>
<p>It looks like the Biden administration is putting its foot on the brakes when it comes to sanctioning the sale of NVIDIA's high-end AI equipment to hostile nations like China since now, the rumors of a potential H20 AI GPU ban are looming in the markets, due to which, Team Green has reportedly halted the sale of its accelerator to Chinese companies, as reported by <a href="https://money.udn.com/money/story/5603/8242728?from=edn_hottest_index">Taiwan Economic Daily</a>. It is said that NVIDIA has stopped accepting new orders for the H20 accelerator and hasn't specified a reason behind it, but it's highly likely that the firm is prepping for a potential revision in the US trade policy.</p>
<p>The investment bank Jefferies pointed out that the US might implement additional restrictions in its review of semiconductor export policies in October, including the decision to ban the trade of NVIDIA's H20 AI GPU. It is estimated that if an H20 ban is implemented, NVIDIA <a href="https://wccftech.com/nvidia-generate-12-billion-china-despite-restrictions-h20-ai-gpu-massive-demand/">might lose up to $12 billion of revenue</a> from mainland China alone, which would be a huge blow to the firm's sustainability in the domestic markets.</p>
<p>After the ban of the H100, NVIDIA's H20 proved to be a phenomenal replacement, attracting the interest of all regional tech giants, which is why a ban will impact NVIDIA's business in China massively. It's important to note that nothing is official right now, and it is said that Team Green is pressing the US administration not to proceed with the "H20 ban" decision, but given past experiences, it won't be wrong to say that this particular move is imminent.</p>
<p>If we look at a larger scale, the export control policies implemented by the US in the past year or so haven't worked out quite well when it comes to limiting the influence of AI developments in China, given that individuals/organizations have found new "loopholes," which act as compensation. One such example is the <a href="https://wccftech.com/nvidia-ai-chip-renting-services-china-cheaper-than-us/">recent boom in GPU rental servicing</a> and how firms established in countries such as the UAE provide computing renting options to clients in China, which is also based on NVIDIA's cutting-edge AI accelerators.</p>


Macro Economic Events

Legal

Global

Economics

NVDA

"NVIDIA's H20 AI Accelerators Might Face The Next 'US Ban', Team Green Stops Taking New Orders In China" - WFFCtech

<p>Allegations of predatory contracts within Missouri's social <a href="https://www.benzinga.com/cannabis">equity cannabis program</a> have surfaced, raising concerns about the integrity of the system.</p>
<p>A recent <a href="https://missouriindependent.com/2024/09/23/alleged-predatory-contracts-continue-to-surface-in-missouri-social-equity-marijuana-program/">investigation</a> by The Missouri Independent<strong> </strong>revealed a troubling case involving <strong>Destiny Brown</strong>, a Black woman who believed she was being offered ownership of a cannabis dispensary and significant financial backing to compete for a license in the state's social equity lottery.</p>
<p>However, Brown unknowingly signed a contract that granted control of the business to investor <strong>Michael Halow</strong>.</p>
<p>Halow, who was unable to qualify for a license himself due to a felony on his record, used Brown's qualifications to secure the license in her name. </p>
<p>Once Brown realized the <a href="https://www.benzinga.com/markets/cannabis/24/07/40021274/missouri-cannabis-leader-faces-allegations-of-using-predatory-contracts-to-exploit-social-equity">exploitative nature</a> of the agreement, she sought legal assistance and severed ties with Halow. </p>
<p>Missouri regulators, upon further investigation, revoked six licenses tied to Halow and revealed a pattern of similar contracts used by other applicants. These contracts have been <a href="https://www.benzinga.com/markets/cannabis/23/12/36313173/social-equity-or-greedy-play-missouris-cannabis-license-controversy-heats-up">under investigation</a> at least since last year.</p>
<h3 class="wp-block-heading">Exploitative Practices And Systematic Abuse</h3>
<p>Brown&#8217;s case is not an isolated incident. </p>
<p>The investigation also uncovered multiple examples of out-of-state companies and cannabis industry insiders exploiting the social equity program by manipulating disadvantaged applicants. </p>
<p>A common tactic includes flooding the lottery with numerous applications under qualified applicants, only to secure contracts that transfer business control to investors once licenses are granted. In these predatory arrangements, the applicant receives little to no benefit while the investor maintains full control of the business.</p>
<ul>
<li><strong><em>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;</em></strong><a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener"><strong><em>here</em></strong></a><strong><em>. If you're serious about the business, you can't afford to miss out.</em></strong></li>
</ul>
<p>Missouri&#8217;s microbusiness program was designed to help disadvantaged groups, including disabled veterans and those affected by non-violent drug offenses.</p>
<p>The <strong>Missouri Division of Cannabis Regulation</strong> continues to investigate these cases, and more revocations are expected as the scope of abuse becomes clearer.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40446319/yet-again-massive-cannabis-product-recall-rocks-missouri-weed-industry-135-000-products-quaranti">Yet Again, Massive Cannabis Product Recall Rocks Missouri Weed Industry: 135,000 Products Quarantined</a></strong></p>
<h3 class="wp-block-heading">Similar Practices Elsewhere</h3>
<p>Missouri is not the only state grappling with the poor performance of its social equity programs.</p>
<p>Similar <strong>predatory practices</strong> <strong>have surfaced in New York and Arizona</strong>, where social equity cannabis programs are facing scrutiny for allowing private interests to exploit disadvantaged applicants. </p>
<p>In New York, a public-private fund intended to help those affected by discriminatory drug laws <a href="https://www.benzinga.com/markets/cannabis/24/06/39336860/unscrupulous-practices-going-on-in-new-york-say-state-senators-about-150m-loan-for-beleaguered-c">has been criticized </a>for favoring private equity firms over qualified applicants. The fund&#8217;s restrictive loan terms and high interest rates have left many licensees struggling to maintain control of their businesses. Also, social equity in the state has faced <a href="https://www.benzinga.com/markets/cannabis/24/07/39694320/licensed-but-closed-new-yorks-cannabis-dream-faces-bureaucratic-nightmare">severe bureaucratic constraints.</a></p>
<p>In Arizona, some have employed <span style="box-sizing: border-box; margin: 0px; padding: 0px;"><a href="https://www.benzinga.com/markets/cannabis/24/01/36720312/arizonas-social-equity-ambitions-in-cannabis-licensing-face-corporate-dominance" target="_blank" rel="noopener">tactics similar to</a></span> those found in <a href="https://www.benzinga.com/topic/missouri-cannabis">Missouri</a>, flooding the state's application process and using complex contracts to exploit social equity applicants.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cannabis/24/09/40945349/cannabis-companies-have-missouris-governor-beat-hemp-thc-products-sales-resume-as-stricter-contr">Cannabis Companies Have Missouri&#8217;s Governor Beat: Hemp-THC Products Sales Resume As Stricter Controls Replace Sweeping Ban</a></strong></li>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/40805538/missouri-joins-crackdown-on-unregulated-cannabis-announces-new-taskforce-as-national-hemp-debate"><strong>Missouri Joins Crackdown On Unregulated Cannabis, Announces New Taskforce As National Hemp Debate Rages</strong></a></li>
</ul>
<p><em>Cover: AI generated image</em></p>


Predatory Cannabis Contracts Allegedly Emerge In Missouri's Social Equity Program

<p><a href="https://www.barrons.com/articles/microsoft-stock-nuclear-power-6c764e54" title="https://www.barrons.com/articles/microsoft-stock-nuclear-power-6c764e54">https://www.barrons.com/articles/microsoft-stock-nuclear-power-6c764e54</a></p>


MSFT

'Microsoft Nuclear Deal Should Be 'Fast-Tracked': Pennsylvania Gov. Shapiro' - Barron's

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>McDonald's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MCD, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 18 uncommon options trades for McDonald's.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 38% bullish and 38%, bearish.</p>
<p>Out of all of the special options we uncovered, 8 are puts, for a total amount of $362,592, and 10 are calls, for a total amount of $564,277.</p>
<h3>Predicted Price Range</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $230.0 to $310.0 for McDonald's during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for McDonald's's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of McDonald's's whale trades within a strike price range from $230.0 to $310.0 in the last 30 days. </p>
<h3>McDonald's Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727118938_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MCD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$35.45</td>
<td>$34.1</td>
<td>$34.1</td>
<td>$280.00</td>
<td>$85.2K</td>
<td>1.3K</td>
<td style="text-align: right;">125</td>
</tr>
<tr>
<td>MCD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$34.65</td>
<td>$34.0</td>
<td>$34.0</td>
<td>$280.00</td>
<td>$85.0K</td>
<td>1.3K</td>
<td style="text-align: right;">75</td>
</tr>
<tr>
<td>MCD</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$34.55</td>
<td>$33.25</td>
<td>$34.0</td>
<td>$280.00</td>
<td>$85.0K</td>
<td>1.3K</td>
<td style="text-align: right;">25</td>
</tr>
<tr>
<td>MCD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$35.55</td>
<td>$33.75</td>
<td>$34.0</td>
<td>$280.00</td>
<td>$85.0K</td>
<td>1.3K</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>MCD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$11.8</td>
<td>$11.7</td>
<td>$11.7</td>
<td>$305.00</td>
<td>$51.4K</td>
<td>233</td>
<td style="text-align: right;">88</td>
</tr>
</tbody>
</table>
</p>
<h3>About McDonald's</h3>
<p>McDonald's is the largest restaurant owner-operator in the world, with 2023 system sales of $130 billion across nearly than 42,000 stores and 115 markets. McDonald's pioneered the franchise model, building its footprint through partnerships with independent restaurant franchisees and master franchise partners around the globe. The firm earns roughly 60% of its revenue from franchise royalty fees and lease payments, with most of the remainder coming from company-operated stores across its three core segments: the United States, internationally operated markets, and international developmental/licensed markets.</p>
<p>After a thorough review of the options trading surrounding McDonald's, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Present Market Standing of McDonald's</h3>
<ul>
<li>With a volume of 1,354,123, the price of MCD is up 0.32% at $297.79. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 35 days.</li>
</ul>
<h3>Expert Opinions on McDonald's</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $324.6.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Neutral rating for McDonald's, targeting a price of $301.<br />
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on McDonald's with a target price of $290.<br />
&#x2A; An analyst from Tigress Financial has decided to maintain their Buy rating on McDonald's, which currently sits at a price target of $360.<br />
&#x2A; Consistent in their evaluation, an analyst from Loop Capital keeps a Buy rating on McDonald's with a target price of $342.<br />
&#x2A; Consistent in their evaluation, an analyst from Jefferies keeps a Buy rating on McDonald's with a target price of $330. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest McDonald's options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Check Out What Whales Are Doing With MCD

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Philip Morris Intl</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with PM, it often means somebody knows something is about to happen.</p>
<p>Today, Benzinga's options scanner spotted 11 options trades for <strong>Philip Morris Intl</strong>.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 27% bullish and 45%, bearish.</p>
<p>Out of all of the options we uncovered, there was 1 put, for a total amount of $89,100, and 10, calls, for a total amount of $459,325.</p>
<h3>Expected Price Movements</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $90.0 to $125.0 for Philip Morris Intl over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Philip Morris Intl's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Philip Morris Intl's whale activity within a strike price range from $90.0 to $125.0 in the last 30 days. </p>
<h3>Philip Morris Intl 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727118933_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>PM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$12.5</td>
<td>$12.3</td>
<td>$12.37</td>
<td>$110.00</td>
<td>$92.7K</td>
<td>6.4K</td>
<td style="text-align: right;">81</td>
</tr>
<tr>
<td>PM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$1.8</td>
<td>$1.7</td>
<td>$1.8</td>
<td>$115.00</td>
<td>$89.1K</td>
<td>48</td>
<td style="text-align: right;">508</td>
</tr>
<tr>
<td>PM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/27/24</td>
<td>$11.0</td>
<td>$10.9</td>
<td>$10.95</td>
<td>$110.00</td>
<td>$85.4K</td>
<td>88</td>
<td style="text-align: right;">87</td>
</tr>
<tr>
<td>PM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/11/24</td>
<td>$6.3</td>
<td>$6.1</td>
<td>$6.18</td>
<td>$115.00</td>
<td>$46.3K</td>
<td>75</td>
<td style="text-align: right;">75</td>
</tr>
<tr>
<td>PM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$4.1</td>
<td>$4.0</td>
<td>$4.1</td>
<td>$120.00</td>
<td>$41.0K</td>
<td>152</td>
<td style="text-align: right;">106</td>
</tr>
</tbody>
</table>
</p>
<h3>About Philip Morris Intl</h3>
<p>Created from the international operations of Altria in 2008, Philip Morris International sells cigarettes and reduced-risk products, including heatsticks, vapes, and oral nicotine offerings primarily outside of the US. With the 2022 acquisition of Swedish Match, a leading manufacturer of traditional oral tobacco products and nicotine pouches primarily in the US and Scandinavia, PMI has not only diversified away from smokeable products but also gained a toehold into the US to sell its iQOS heatsticks.</p>
<h3>Present Market Standing of Philip Morris Intl</h3>
<ul>
<li>With a trading volume of 1,936,636, the price of PM is up by 0.16%, reaching $120.98.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 29 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Philip Morris Intl</h3>
<p>In the last month, 4 experts released ratings on this stock with an average target price of $131.75.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Philip Morris Intl, targeting a price of $145.<br />
&#x2A; An analyst from Stifel persists with their Buy rating on Philip Morris Intl, maintaining a target price of $138.<br />
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on Philip Morris Intl, which currently sits at a price target of $139.<br />
&#x2A; An analyst from UBS persists with their Sell rating on Philip Morris Intl, maintaining a target price of $105. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Philip Morris Intl options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


A Closer Look at Philip Morris Intl's Options Market Dynamics

<p>Deep-pocketed investors have adopted a bearish approach towards Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MRK usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for Merck &amp; Co. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 45% leaning bullish and 54% bearish. Among these notable options, 2 are puts, totaling $84,071, and 9 are calls, amounting to $500,344.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $110.0 and $125.0 for Merck &amp; Co, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Merck &amp; Co stands at 3469.29, with a total volume reaching 7,958.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Merck &amp; Co, situated within the strike price corridor from $110.0 to $125.0, throughout the last 30 days.</p>
<h3>Merck &amp; Co 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727118928_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$1.74</td>
<td>$1.65</td>
<td>$1.68</td>
<td>$117.00</td>
<td>$120.4K</td>
<td>0</td>
<td>1.0K</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$2.77</td>
<td>$2.72</td>
<td>$2.72</td>
<td>$120.00</td>
<td>$98.3K</td>
<td>4.8K</td>
<td>64</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$0.76</td>
<td>$0.72</td>
<td>$0.75</td>
<td>$120.00</td>
<td>$67.2K</td>
<td>9.8K</td>
<td>998</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$9.95</td>
<td>$9.85</td>
<td>$9.89</td>
<td>$115.00</td>
<td>$49.4K</td>
<td>298</td>
<td>4</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$3.0</td>
<td>$2.98</td>
<td>$2.98</td>
<td>$115.00</td>
<td>$45.2K</td>
<td>4.5K</td>
<td>468</td>
</tr>
</tbody>
</table>
</p>
<h3>About Merck &amp; Co</h3>
<p>Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.</p>
<h3>Current Position of Merck &amp; Co</h3>
<ul>
<li>With a trading volume of 3,262,924, the price of MRK is down by -1.08%, reaching $115.9.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 38 days from now.</li>
</ul>
<h3>Expert Opinions on Merck &amp; Co</h3>
<p>A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $155.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $155.<br />
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $155. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Merck &amp; Co with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Merck & Co Unusual Options Activity For September 23

<p><strong>Treasure Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGL#NASDAQ">TGL</a>)</strong> shares are surging following the announcement of a strategic partnership with Credilab on 20 September 2024. The collaboration aims to leverage both companies&#8217; expertise and market resources to drive mutual growth and success.  </p>
<p>Additionally, on the same day, <strong>Mr. Anand Ramakrishnan</strong>, an independent director on Treasure Global&#8217;s Board, resigned immediately. His departure was not due to any dispute or disagreement with the company&#8217;s operations, policies or practices.</p>
<h2 class="wp-block-heading">How To Buy Treasure Global Stock?</h2>
<p>Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. </p>
<p>For example, in Treasure Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGL#NASDAQ">TGL</a>)'s case, it is in the Communication Services sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.</p>
<p><strong>TGL Price Action: </strong>Treasure Global shares were up by 64.3% at $1.11 according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a></p>
<p><figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1722883001180099"><img loading="lazy" decoding="async" width="1024" height="557" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23144355/TGL-1024x557.png" alt="" class="wp-image-561776" style="width:518px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23144355/TGL-1024x557.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23144355/TGL-300x163.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23144355/TGL-768x418.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23144355/TGL.png 1077w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure></p>
<p><strong>See Also:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cannabis/24/09/40989426/conservative-politics-threaten-germanys-cannabis-legalization-plan-whats-going-on">Conservative Politics Threaten Germany&#8217;s Cannabis Legalization Plan: What&#8217;s Going On?</a></strong></li>
</ul>
<p><em>Photo by solarseven on Shutterstock</em>.</p>


Why Treasure Global Shares Are Trading Higher Today

CMCSA

Comcast Launches "Janus" Initiative To Enhance Internet Connectivity Using Cloud And AI Technology, Virtualizing Its Core Network For Faster, More Reliable Service

BridgeBio Pharma ($BBIO) is capturing attention with its unique approach to developing gene-based therapies for cancer and genetic-driven ailments....

A Promising Pipeline Ready to Break out at BridgeBio Pharma (BBIO)

In the very short term, I would say the further downside is likely but not for long. These are not ideal conditions, so either sit it out or make sure you take your profits early.

Patchy And Still Patchy In The Short Term

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2024 Update

J.P. Morgan analyst Anupam Rama has reiterated their bullish stance on BBIO stock, giving a Buy rating on September 4. Anupam Rama's rating is base...

Buy Rating for BridgeBio Pharma Backed by Acoramidis Drug's Promising Data and Market Potential

BridgeBio gets FDA RMAT status for Canavan disease gene therapy

Analyst Jason Zemansky of Bank of America Securities maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report), retaining the price targ...

Buy Rating Affirmed for BridgeBio Pharma Amid Promising Clinical Trials and Strategic Decisions

BridgeBio stock slides on discontinuation of CAH gene therapy

Analyst Mani Foroohar of Leerink Partners maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report), with a price target of $48.00. Mani...

Strategic Refocusing and Financial Prudence Bolster BridgeBio Pharma's Long-term Outlook: Maintaining a Buy Rating

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on BridgeBio Pharma (BBIO – Research Report), retaining the price target of $43.00...

Buy Rating Affirmed for BridgeBio Pharma Amidst Promising Gene Therapy Advancements and Regulatory Milestones

BridgeBio achondroplasia asset infigratinib nabs FDA Breakthrough Therapy status

AAPL

ACHC

ADBE

ADPT

AMAT

AMZN

AVGO

BMRN

DASH

DDOG

DLTR

DOCU

EWTX

FDMT

FERG

INBX

KYKOF

LBPH

NAMS

NFLX

ORIC

PEPG

PHVS

ROIV

RPRX

TMUS

TRVI

TSLA

TTWO

VKTX

WDAY

Press Releases

BridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia

BridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with Multimodal Artificial Intelligence

BridgeBio Pharma to Participate in September Investor Events

BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024

BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension

BRIDGEBIO PHARMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates BridgeBio Pharma, Inc. - BBIO

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program

BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)

BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

BridgeBio Pharma

BridgeBio Pharma (BBIO) Forecast

BridgeBio Pharma (NASDAQ:BBIO) Stock, Quote.Headers.trade-ideas